Status:
COMPLETED
Agaricus Blazei Murill in Patients With Multiple Myeloma
Lead Sponsor:
Ullevaal University Hospital
Conditions:
Multiple Myeloma
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
Extract from the mushroom Agaricus blazei Murill har been shown to have strong immunomodulating properties both in cell cultures, animal models and in humans. Furthermore antitumor properties have bee...
Detailed Description
Patients who are scheduled to undergo high dose chemotherapy for multiple myeloma will receive in addition in a double blinded manner 60 ml of agaricus extract or placebo once daily from the start of ...
Eligibility Criteria
Inclusion
- Patients scheduled to undergo high dose chemotherapy with autologous stem cell support for multiple myeloma
Exclusion
- None
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2014
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00970021
Start Date
June 1 2009
End Date
February 1 2014
Last Update
February 25 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of hematology, Oslo University Hospital, Ullevaal
Oslo, Norway, 0407